BIIB061

DRUG4 trials

Sponsors

Biogen

Conditions

HealthyMultiple SclerosisRelapsing Multiple Sclerosis

Phase 1

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

CompletedNCT02071121

Start: 2013-12-31End: 2014-09-30Updated: 2015-02-02

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

CompletedNCT02228707

Start: 2014-08-31End: 2016-05-31Updated: 2016-06-15

Single-Dose Study of a New Formulation of BIIB061

CompletedNCT02521545

BiogenMultiple Sclerosis

Start: 2015-07-31End: 2015-08-31Updated: 2015-09-07

Phase 2

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

WithdrawnNCT04079088

BiogenRelapsing Multiple Sclerosis

Start: 2021-06-30End: 2024-09-18Updated: 2023-06-01